Marcus Conrad Wins Galenus Award for Ferroptosis Research
Prof. Marcus Conrad, Director at the Institute of Metabolism and Cell Death at Helmholtz Munich, has been awarded the Galenus-von-Pergamon Award in the category of Basic Research. The honor recognizes his pioneering contributions to the field of ferroptosis, a unique form of regulated cell death that has significant implications for various diseases, including cancer and neurodegenerative disorders.
Ferroptosis is an iron-dependent cell death process characterized by the destruction of cell membranes due to oxidative stress. Marcus Conrad and his team have been at the forefront of ferroptosis research for over two decades, playing a key role in uncovering the molecular mechanisms underlying this form of cell death and its role in disease progression. Their work has not only advanced the basic understanding of ferroptosis but has also paved the way for new therapeutic strategies aimed at targeting the process to treat complex diseases.
"This award is not just a recognition of my work, but also of the incredible efforts of my research team and collaborators over the years. It motivates us to continue our quest to explore new therapeutic avenues for ferroptosis-related diseases."
Prof. Marcus Conrad
The Galenus Award, regarded as one of the highest honors in the field of pharmacology and medical research, recognizes outstanding achievements in basic research, drug development, and medical technology. Marcus Conrad’s work exemplifies the profound impact of fundamental research on therapeutic innovation, setting the stage for more effective and personalized medical interventions.